Dept of Pathology, Dartmouth Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756;
Am J Clin Pathol. 2014 Jan;141(1):17-24. doi: 10.1309/AJCPA1L4KPXBJNPG.
Infectious diseases that are largely treatable continue to pose a tremendous burden on the developing world despite the availability of highly potent drugs. The high mortality and morbidity rates of these diseases are largely due to a lack of affordable diagnostics that are accessible to resource-limited areas and that can deliver high-quality results. In fact, modified molecular diagnostics for infectious diseases were rated as the top biotechnology to improve health in developing countries.
In this review, we describe the characteristics of accessible molecular diagnostic tools and discuss the challenges associated with implementing such tools at low infrastructure sites.
We highlight our experience as part of the "Grand Challenge" project supported by the Gates Foundation for addressing global health inequities and describe issues and solutions associated with developing adequate technologies or molecular assays needed for broad access in the developing world.
We believe that sharing this knowledge will facilitate the development of new molecular technologies that are extremely valuable for improving global health.
尽管有高效药物,在发展中国家,许多可治疗的传染病仍造成巨大负担。这些疾病的高死亡率和发病率主要是由于缺乏负担得起的诊断方法,这些方法在资源有限的地区难以获得,并且无法提供高质量的结果。事实上,用于传染病的改良分子诊断被评为改善发展中国家健康的顶级生物技术。
在这篇综述中,我们描述了可及的分子诊断工具的特征,并讨论了在基础设施薄弱的地方实施这些工具所面临的挑战。
我们强调了我们在盖茨基金会支持的“大挑战”项目中的经验,以解决全球卫生不平等问题,并描述了与开发发展中国家广泛应用所需的适当技术或分子检测方法相关的问题和解决方案。
我们相信,分享这些知识将有助于开发新的分子技术,这对于改善全球健康非常有价值。